Diabetes Drug Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)

The report covers Global Diabetes Drug Market Outlook & Trends. The market is Segmented by Drugs (Oral Anti-diabetic Drugs, Insulin, Non-insulin Injectable Drugs, and Combination Drugs) and by Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and Latin America). The report offers the value (in USD million) for the above segments.

Home right-chevron-icon Market Analysis right-chevron-icon Healthcare Research right-chevron-icon Pharmaceuticals Research right-chevron-icon Disease Specific Drugs Research right-chevron-icon Chronic Disorder Drugs Research right-chevron-icon Diabetes Care Drugs Research right-chevron-icon Diabetes Drug Industry

Diabetes Drug Market Size

Diabetes Care Drugs Market Summary
share button
Study Period 2018 - 2028
Market Size (2023) USD 84.56 Billion
Market Size (2028) USD 100.48 Billion
CAGR (2023 - 2028) 3.51 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Diabetes Care Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order
setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Diabetes Drug Market Analysis

The Diabetes Care Drugs Market size is estimated at USD 84.56 billion in 2023, and is expected to reach USD 100.48 billion by 2028, growing at a CAGR of 3.51% during the forecast period (2023-2028).

Diabetes is a chronic, life-threatening disease with no known cure. As per the World Health Organization, there are over 400 million people with diabetes across the world, and its treatment constitutes around 12% of the total healthcare expenditure on a global scale. It has emerged as a global epidemic and afflicted millions worldwide. The significant growth in the market can be attributed to factors, such as the rising prevalence of diabetes and the increasing number of programs initiated by various health organizations related to health awareness. Currently, about 10% of all diabetes cases are Type-1 and the remaining are Type-2.

As of 2021, North America accounted for a major share of the market, followed by Asia-Pacific. The increase in the number of diabetes patients is primarily due to increasing obesity among people caused by unhealthy diets and sedentary lifestyles. The market in Asia-Pacific is mainly driven by increasing demand for diabetes drugs from China and India. Currently, China has over 129 million diabetes patients, while the number of diabetes patients in India is expected to reach 82 million by 2027.

Based on drugs, the insulin segment holds a significant share in the market. Over 100 million people around the world need insulin, including all the people suffering from Type-1 diabetes and between 10% and 25% of people with Type-2 diabetes. Production of insulin is very complex, and there are very few companies in the market that manufacture insulin. Due to this, there is high competition between these manufacturers, who always strive to meet the patient's needs to supply the best-quality insulin.

Diabetes Drug Market Trends

This section covers the major market trends shaping the Diabetes Care Drugs Market according to our research experts:

Insulin Drugs is Having the Highest Market Share in 2021

The insulin segment is expected to increase with a CAGR of over 3% during the forecast period, mainly due to the demand from the Type-1 diabetes population, which was more than 58 million by the end of 2027.

According to the International Diabetes Federation, diabetes patients spent USD 966 billion in 2021, of which, a major chunk was spent by Type-1 diabetes patients on insulin drugs. Few Type-2 diabetes patients also depend on insulin. Although only 10% of the diabetes population is Type-1, their intake of insulin is higher in them. Demand for insulin is driven by an increase in awareness about the benefits of insulin for diabetes patients, especially in emerging economies. Other factors, such as rapid development in insulin delivery systems, drug and analog development by major companies, and the rise in the geriatric and obese population, may fuel the growth of the insulin market.

Diabetes Care Drugs Market: Revenue in USD million, Insulin, Global, 2021-2027

North America is Expected to Dominate the Diabetes Drugs Market.

North America dominates the global insulin therapeutics market, owing to the high prevalence of diabetes in the region because of the sedentary lifestyle and the launch of new drugs in the region. The United States is expected to grow tremendously during the forecast period, owing to factors, such as the high prevalence of obesity and increasing awareness regarding diabetes care in the region. North America remained the largest market for insulin drugs, primarily due to high demand from the United States.

In January 2020, Novo Nordisk announced that the US Food and Drug Administration (FDA) had approved Fiasp (insulin aspart injection) 100 u/mL for use as a new mealtime insulin option for children with diabetes. Such developments are expected to increase the sales of Fiasp during the forecast period.

Thus, owing to the above factors it is expected to drive the market growth over the forecast period.

Diabetes Drugs Market: Revenue Share (%), by Geography, 2021

Diabetes Drug Industry Overview

The diabetes drugs market is moderately fragmented, with few significant and generic players. The insulin drugs and Sglt-2 drugs market are dominated by a few major players, like Novo-Nordisk, Sanofi, AstraZeneca, and Bristol Myers Squibb. The market for oral drugs, like Sulfonylureas and Meglitinides, comprises more generic players. The intensity of competition among the players is high, as each player is striving to develop new drugs and offer them at competitive pricing. Furthermore, to increase their market shares, players are tapping into new markets, especially emerging economies where the demand is very high compared to the supply.

Diabetes Drug Market Leaders

  1. Novo Nordisk

  2. Sanofi

  3. AstraZeneca

  4. Boehringer Ingelheim

  5. Eli Lilly and Company

*Disclaimer: Major Players sorted in no particular order

Diabetes Care Drugs Market Concentration

Diabetes Drug Market News

  • In May 2022, the U.S. Food and Drug Administration approved Mounjaro (tirzepatide) injection to improve blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise. Mounjaro was effective at improving blood sugar and was more effective than the other diabetes therapies with which it was compared in clinical studies.
  • In 2021, the U.S. Food and Drug Administration approved the first interchangeable biosimilar insulin product Semglee (insulin glargine). Semglee is the first interchangeable biosimilar product approved in the U.S. for the treatment of diabetes. Approval of these insulin products can provide patients with additional safe, high-quality, and potentially cost-effective options for treating diabetes.

Diabetes Drug Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

    3. 4.3 Market Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drugs

      1. 5.1.1 Oral Anti-diabetic drugs (Value and Volume 2016-2027)

        1. 5.1.1.1 Biguanides

          1. 5.1.1.1.1 Metformin

        2. 5.1.1.2 Alpha-glucosidase Inhibitors

        3. 5.1.1.3 Dopamine -D2 Receptor Agonist

          1. 5.1.1.3.1 Cycloset (Bromocriptin)

        4. 5.1.1.4 Sodium-glucose Cotransport -2 (SGLT-2) Inhibitors

          1. 5.1.1.4.1 Invokana (Canagliflozin)

          2. 5.1.1.4.2 Jardiance (Empagliflozin)

          3. 5.1.1.4.3 Farxiga/Forxiga (Dapagliflozin)

          4. 5.1.1.4.4 Suglat (Ipragliflozin)

        5. 5.1.1.5 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

          1. 5.1.1.5.1 Januvia (Sitagliptin)

          2. 5.1.1.5.2 Onglyza (Saxagliptin)

          3. 5.1.1.5.3 Tradjenta (Linagliptin)

          4. 5.1.1.5.4 Vipidia/Nesina (Alogliptin)

          5. 5.1.1.5.5 Galvus (Vildagliptin)

        6. 5.1.1.6 Sulfonylureas

        7. 5.1.1.7 Meglitinides

      2. 5.1.2 Insulin (Value and Volume 2016-2027)

        1. 5.1.2.1 Basal or Long-acting Insulin

          1. 5.1.2.1.1 Lantus (Insulin Glargine)

          2. 5.1.2.1.2 Levemir (Insulin Detemir)

          3. 5.1.2.1.3 Toujeo (Insulin Glargine)

          4. 5.1.2.1.4 Tresiba (Insulin Degludec)

          5. 5.1.2.1.5 Basaglar (Insulin Glargine)

        2. 5.1.2.2 Bolus or Fast-acting Insulin

          1. 5.1.2.2.1 NovoRapid/Novolog (Insulin Aspart)

          2. 5.1.2.2.2 Humalog (Insulin Lispro)

          3. 5.1.2.2.3 Apidra (Insulin Glulisine)

        3. 5.1.2.3 Traditional Human Insulin

          1. 5.1.2.3.1 Novolin/Actrapid/Insulatard

          2. 5.1.2.3.2 Humulin

          3. 5.1.2.3.3 Insuman

        4. 5.1.2.4 Biosimilar Insulin

          1. 5.1.2.4.1 Insulin Glargine Biosimilars

          2. 5.1.2.4.2 Human Insulin Biosimilars

      3. 5.1.3 Non-insulin Injectable Drug (Value and Volume 2016-2027)

        1. 5.1.3.1 GLP-1 Receptor Agonists

          1. 5.1.3.1.1 Victoza (Liraglutide)

          2. 5.1.3.1.2 Byetta (Exenatide)

          3. 5.1.3.1.3 Bydureon (Exenatide)

          4. 5.1.3.1.4 Trulicity (Dulaglutide)

          5. 5.1.3.1.5 Lyxumia (Lixisenatide)

        2. 5.1.3.2 Amylin Analogue

          1. 5.1.3.2.1 Symlin (Pramlintide)

      4. 5.1.4 Combination Drug (Value and Volume 2016-2027)

        1. 5.1.4.1 Combination Insulin

          1. 5.1.4.1.1 NovoMix (Biphasic Insulin Aspart)

          2. 5.1.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

          3. 5.1.4.1.3 Xultophy (Insulin Degludec and Liraglutide)

        2. 5.1.4.2 Oral Combination

          1. 5.1.4.2.1 Janumet (Sitagliptin and Metformin HCl)

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States (Value and Volume 2016-2027)

          1. 5.2.1.1.1 Oral Anti-diabetic Drugs

          2. 5.2.1.1.2 Insulin

          3. 5.2.1.1.3 Non-insulin Injectable Drugs

          4. 5.2.1.1.4 Combination Drugs

        2. 5.2.1.2 Canada (Value and Volume 2016-2027)

          1. 5.2.1.2.1 Oral Anti-diabetic Drugs

          2. 5.2.1.2.2 Insulin

          3. 5.2.1.2.3 Non-insulin Injectable Drugs

          4. 5.2.1.2.4 Combination Drugs

        3. 5.2.1.3 Rest of North America (Value and Volume 2016-2027)

          1. 5.2.1.3.1 Oral Anti-diabetic Drugs

          2. 5.2.1.3.2 Insulin

          3. 5.2.1.3.3 Non-insulin Injectable Drugs

          4. 5.2.1.3.4 Combination Drugs

      2. 5.2.2 Europe

        1. 5.2.2.1 France (Value and Volume 2016-2027)

          1. 5.2.2.1.1 Oral Anti-diabetic Drugs

          2. 5.2.2.1.2 Insulin

          3. 5.2.2.1.3 Non-insulin Injectable Drugs

          4. 5.2.2.1.4 Combination Drugs

        2. 5.2.2.2 Germany (Value and Volume 2016-2027)

          1. 5.2.2.2.1 Oral Anti-diabetic Drugs

          2. 5.2.2.2.2 Insulin

          3. 5.2.2.2.3 Non-insulin Injectable Drugs

          4. 5.2.2.2.4 Combination Drugs

        3. 5.2.2.3 Italy (Value and Volume 2016-2027)

          1. 5.2.2.3.1 Oral Anti-diabetic Drugs

          2. 5.2.2.3.2 Insulin

          3. 5.2.2.3.3 Non-insulin Injectable Drugs

          4. 5.2.2.3.4 Combination Drugs

        4. 5.2.2.4 Spain (Value and Volume 2016-2027)

          1. 5.2.2.4.1 Oral Anti-diabetic Drugs

          2. 5.2.2.4.2 Insulin

          3. 5.2.2.4.3 Non-insulin Injectable Drugs

          4. 5.2.2.4.4 Combination Drugs

        5. 5.2.2.5 United Kingdom (Value and Volume 2016-2027)

          1. 5.2.2.5.1 Oral Anti-diabetic Drugs

          2. 5.2.2.5.2 Insulin

          3. 5.2.2.5.3 Non-insulin Injectable Drugs

          4. 5.2.2.5.4 Combination Drugs

        6. 5.2.2.6 Russia (Value and Volume 2016-2027)

          1. 5.2.2.6.1 Oral Anti-diabetic Drugs

          2. 5.2.2.6.2 Insulin

          3. 5.2.2.6.3 Non-insulin Injectable Drugs

          4. 5.2.2.6.4 Combination Drugs

        7. 5.2.2.7 Rest of Europe (Value and Volume 2016-2027)

          1. 5.2.2.7.1 Oral Anti-diabetic Drugs

          2. 5.2.2.7.2 Insulin

          3. 5.2.2.7.3 Non-insulin Injectable Drugs

          4. 5.2.2.7.4 Combination Drugs

      3. 5.2.3 Latin America

        1. 5.2.3.1 Mexico (Value and Volume 2016-2027)

          1. 5.2.3.1.1 Oral Anti-diabetic Drugs

          2. 5.2.3.1.2 Insulin

          3. 5.2.3.1.3 Non-insulin Injectable Drugs

          4. 5.2.3.1.4 Combination Drugs

        2. 5.2.3.2 Brazil (Value and Volume 2016-2027)

          1. 5.2.3.2.1 Oral Anti-diabetic Drugs

          2. 5.2.3.2.2 Insulin

          3. 5.2.3.2.3 Non-insulin Injectable Drugs

          4. 5.2.3.2.4 Combination Drugs

        3. 5.2.3.3 Rest of Latin America (Value and Volume 2016-2027)

          1. 5.2.3.3.1 Oral Anti-diabetic Drugs

          2. 5.2.3.3.2 Insulin

          3. 5.2.3.3.3 Non-insulin Injectable Drugs

          4. 5.2.3.3.4 Combination Drugs

      4. 5.2.4 Asia-Pacific

        1. 5.2.4.1 Japan (Value and Volume 2016-2027)

          1. 5.2.4.1.1 Oral Anti-diabetic Drugs

          2. 5.2.4.1.2 Insulin

          3. 5.2.4.1.3 Non-insulin Injectable Drugs

          4. 5.2.4.1.4 Combination Drugs

        2. 5.2.4.2 South Korea (Value and Volume 2016-2027)

          1. 5.2.4.2.1 Oral Anti-diabetic Drugs

          2. 5.2.4.2.2 Insulin

          3. 5.2.4.2.3 Non-insulin Injectable Drugs

          4. 5.2.4.2.4 Combination Drugs

        3. 5.2.4.3 China (Value and Volume 2016-2027)

          1. 5.2.4.3.1 Oral Anti-diabetic Drugs

          2. 5.2.4.3.2 Insulin

          3. 5.2.4.3.3 Non-insulin Injectable Drugs

          4. 5.2.4.3.4 Combination Drugs

        4. 5.2.4.4 India (Value and Volume 2016-2027)

          1. 5.2.4.4.1 Oral Anti-diabetic Drugs

          2. 5.2.4.4.2 Insulin

          3. 5.2.4.4.3 Non-insulin Injectable Drugs

          4. 5.2.4.4.4 Combination Drugs

        5. 5.2.4.5 Australia (Value and Volume 2016-2027)

          1. 5.2.4.5.1 Oral Anti-diabetic Drugs

          2. 5.2.4.5.2 Insulin

          3. 5.2.4.5.3 Non-insulin Injectable Drugs

          4. 5.2.4.5.4 Combination Drugs

        6. 5.2.4.6 Vietnam (Value and Volume 2016-2027)

          1. 5.2.4.6.1 Oral Anti-diabetic Drugs

          2. 5.2.4.6.2 Insulin

          3. 5.2.4.6.3 Non-insulin Injectable Drugs

          4. 5.2.4.6.4 Combination Drugs

        7. 5.2.4.7 Malaysia (Value and Volume 2016-2027)

          1. 5.2.4.7.1 Oral Anti-diabetic Drugs

          2. 5.2.4.7.2 Insulin

          3. 5.2.4.7.3 Non-insulin Injectable Drugs

          4. 5.2.4.7.4 Combination Drugs

        8. 5.2.4.8 Indonesia (Value and Volume 2016-2027)

          1. 5.2.4.8.1 Oral Anti-diabetic Drugs

          2. 5.2.4.8.2 Insulin

          3. 5.2.4.8.3 Non-insulin Injectable Drugs

          4. 5.2.4.8.4 Combination Drugs

        9. 5.2.4.9 Philippines (Value and Volume 2016-2027)

          1. 5.2.4.9.1 Oral Anti-diabetic Drugs

          2. 5.2.4.9.2 Insulin

          3. 5.2.4.9.3 Non-insulin Injectable Drugs

          4. 5.2.4.9.4 Combination Drugs

        10. 5.2.4.10 Thailand (Value and Volume 2016-2027)

          1. 5.2.4.10.1 Oral Anti-diabetic Drugs

          2. 5.2.4.10.2 Insulin

          3. 5.2.4.10.3 Non-insulin Injectable Drugs

          4. 5.2.4.10.4 Combination Drugs

        11. 5.2.4.11 Rest of Asia-Pacific (Value and Volume 2016-2027)

          1. 5.2.4.11.1 Oral Anti-diabetic Drugs

          2. 5.2.4.11.2 Insulin

          3. 5.2.4.11.3 Non-insulin Injectable Drugs

          4. 5.2.4.11.4 Combination Drugs

      5. 5.2.5 Middle-East and Africa

        1. 5.2.5.1 Saudi Arabia (Value and Volume 2016-2027)

          1. 5.2.5.1.1 Oral Anti-diabetic Drugs

          2. 5.2.5.1.2 Insulin

          3. 5.2.5.1.3 Non-insulin Injectable Drugs

          4. 5.2.5.1.4 Combination Drugs

        2. 5.2.5.2 Iran (Value and Volume 2016-2027)

          1. 5.2.5.2.1 Oral Anti-diabetic Drugs

          2. 5.2.5.2.2 Insulin

          3. 5.2.5.2.3 Non-insulin Injectable Drugs

          4. 5.2.5.2.4 Combination Drugs

        3. 5.2.5.3 Egypt (Value and Volume 2016-2027)

          1. 5.2.5.3.1 Oral Anti-diabetic Drugs

          2. 5.2.5.3.2 Insulin

          3. 5.2.5.3.3 Non-insulin Injectable Drugs

          4. 5.2.5.3.4 Combination Drugs

        4. 5.2.5.4 Oman (Value and Volume 2016-2027)

          1. 5.2.5.4.1 Oral Anti-diabetic Drugs

          2. 5.2.5.4.2 Insulin

          3. 5.2.5.4.3 Non-insulin Injectable Drugs

          4. 5.2.5.4.4 Combination Drugs

        5. 5.2.5.5 South Africa (Value and Volume 2016-2027)

          1. 5.2.5.5.1 Oral Anti-diabetic Drugs

          2. 5.2.5.5.2 Insulin

          3. 5.2.5.5.3 Non-insulin Injectable Drugs

          4. 5.2.5.5.4 Combination Drugs

        6. 5.2.5.6 Rest of Middle-East and Africa (Value and Volume 2016-2027)

          1. 5.2.5.6.1 Oral Anti-diabetic Drugs

          2. 5.2.5.6.2 Insulin

          3. 5.2.5.6.3 Non-insulin Injectable Drugs

          4. 5.2.5.6.4 Combination Drugs

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 Diabetes Population (2016-2027)

    2. 6.2 Type-2 Diabetes Population (2016-2027)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 Company Profiles

      1. 7.1.1 Novo Nordisk

      2. 7.1.2 Sanofi

      3. 7.1.3 Eli Lilly and Company

      4. 7.1.4 Biocon

      5. 7.1.5 AstraZeneca

      6. 7.1.6 Bristol Myers Squibb

      7. 7.1.7 Boehringer Ingelheim

      8. 7.1.8 Mylan

      9. 7.1.9 Pfizer

      10. 7.1.10 Johnson & Johnson

      11. 7.1.11 Merck & Co.

      12. 7.1.12 Novartis

      13. 7.1.13 Astellas Pharma

      14. 7.1.14 Teva Pharmaceuticals

    3. 7.2 Company Share Analysis

      1. 7.2.1 Insulin Drugs

        1. 7.2.1.1 Novo Nordisk

        2. 7.2.1.2 Sanofi

        3. 7.2.1.3 Eli Lilly and Company

        4. 7.2.1.4 Others

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

Diabetes Drug Industry Segmentation

Diabetes or diabetes mellitus describes a group of metabolic disorders characterized by a high blood sugar level in a person. With diabetes, the body either does not produce enough insulin or the body's cells do not respond properly to insulin, or both. The diabetes care drugs market is segmented by drugs into Insulin (Basal or Long-Acting, Bolus or Fast-Acting, Traditional Human Insulin Drugs, and Insulin Biosimilars), Oral Anti-Diabetic Drugs (Alpha-Glucosidase Inhibitors, DPP-4 Inhibitors, and SGLT-2 Inhibitors), Non-Insulin Injectable Drugs (GLP-1 Receptor Agonists, and Amylin Analogue), and Combination Drugs (Combination Insulin, Oral Combination).

By Drugs
Oral Anti-diabetic drugs (Value and Volume 2016-2027)
Biguanides
Metformin
Alpha-glucosidase Inhibitors
Dopamine -D2 Receptor Agonist
Cycloset (Bromocriptin)
Sodium-glucose Cotransport -2 (SGLT-2) Inhibitors
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
Januvia (Sitagliptin)
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina (Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas
Meglitinides
Insulin (Value and Volume 2016-2027)
Basal or Long-acting Insulin
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast-acting Insulin
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulin
Novolin/Actrapid/Insulatard
Humulin
Insuman
Biosimilar Insulin
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Non-insulin Injectable Drug (Value and Volume 2016-2027)
GLP-1 Receptor Agonists
Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Amylin Analogue
Symlin (Pramlintide)
Combination Drug (Value and Volume 2016-2027)
Combination Insulin
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Oral Combination
Janumet (Sitagliptin and Metformin HCl)
Geography
North America
United States (Value and Volume 2016-2027)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Canada (Value and Volume 2016-2027)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Rest of North America (Value and Volume 2016-2027)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Europe
France (Value and Volume 2016-2027)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Germany (Value and Volume 2016-2027)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Italy (Value and Volume 2016-2027)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Spain (Value and Volume 2016-2027)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
United Kingdom (Value and Volume 2016-2027)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Russia (Value and Volume 2016-2027)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Rest of Europe (Value and Volume 2016-2027)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Latin America
Mexico (Value and Volume 2016-2027)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Brazil (Value and Volume 2016-2027)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Rest of Latin America (Value and Volume 2016-2027)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Asia-Pacific
Japan (Value and Volume 2016-2027)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
South Korea (Value and Volume 2016-2027)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
China (Value and Volume 2016-2027)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
India (Value and Volume 2016-2027)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Australia (Value and Volume 2016-2027)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Vietnam (Value and Volume 2016-2027)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Malaysia (Value and Volume 2016-2027)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Indonesia (Value and Volume 2016-2027)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Philippines (Value and Volume 2016-2027)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Thailand (Value and Volume 2016-2027)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Rest of Asia-Pacific (Value and Volume 2016-2027)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Middle-East and Africa
Saudi Arabia (Value and Volume 2016-2027)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Iran (Value and Volume 2016-2027)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Egypt (Value and Volume 2016-2027)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Oman (Value and Volume 2016-2027)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
South Africa (Value and Volume 2016-2027)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Rest of Middle-East and Africa (Value and Volume 2016-2027)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs

Report scope can be customized per your requirements. Click here.

You can also purchase parts of this report. Do you want to check out a section wise price list?

Diabetes Drug Market Research FAQs

The Diabetes Care Drugs Market size is expected to reach USD 84.56 billion in 2023 and grow at a CAGR of 3.51% to reach USD 100.48 billion by 2028.

In 2023, the Diabetes Care Drugs Market size is expected to reach USD 84.56 billion.

Novo Nordisk, Sanofi, AstraZeneca, Boehringer Ingelheim and Eli Lilly and Company are the major companies operating in the Diabetes Care Drugs Market.

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2023-2028).

In 2023, the North America accounts for the largest market share in the Diabetes Care Drugs Market.

Diabetes Drug Industry Report

Statistics for the 2023 Diabetes Drug market share, size and revenue growth rate, created by Mordor Intelligenceā„¢ Industry Reports. Diabetes Drug analysis includes a market forecast outlook to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Diabetes Drug Market Report Snapshots

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!